

Author Relationships With Industry and Other Entities (Comprehensive)–A Systematic Review for the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay (June 2017)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
David J Slotwiner (Chair)	Chief, Division of Cardiology. Assistant Professor of Medicine, School of Health Policy & Research, New York Presbyterian Queens/Weill Cornell Medical College	None	None	None	None	None	None
Merritt H Raitt (Vice Chair)	Chief of Cardiology, VA Portland Health Care System, Director, VA National Cardiac Device Surveillance Program	None	None	None	None	None	None
Freddy Del-Carpio Munoz	Assistant Professor of Medicine, Mayo Clinic College of Medicine and Science. Rochester, MN.	None	None	None	None	None	None
Siva K Mulpuru	Associate Professor of Medicine, Mayo Clinic College of Medicine and Sciences, Rochester, MN.	None	None	None	None	● Mayo Clinic*	None
Naseer Nasser	Attending Cardiac Electrophysiologist South Bend Clinic	None	None	None	None	None	None
Pamela N Peterson	Associate Professor, Medicine, University of Colorado School of Medicine, Cardiology Denver, CO	None	None	None	None	● AHA (Associate Editor)†	None

This table represents all relationships of evidence review committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥\$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy.

*This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no *direct* or *institutional* relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy.

†Significant relationship.

ACC indicates American College of Cardiology; AHA, American Heart Association; HRS, Heart Rhythm Society

CMS reported research payments to Dr. Del-Carpio Munoz in November 2016. Dr. Del-Carpio Munoz personally receives no money from Boehringer Ingelheim as the PI for the GLORIA registry; his hospital receives some reimbursement. Boehringer Ingelheim was deemed not relevant to the ERC report.